BioMed X and AbbVie Launch Neuroscience Collaboration to Target Anhedonia Mechanisms
Key Insights
BioMed X (search) and AbbVie (search) announced a new collaborative research project focused on developing circuit-based model systems of anhedonia (search) at the BioMed X Institute in New Haven, Connecticut.
The collaboration aims to identify specific mechanisms underlying anhedonia (search), a challenging symptom of depression (search) and other psychiatric conditions (search) involving complex neurotransmitter systems (search) and brain regions.
Researchers worldwide are invited to submit proposals integrating interdisciplinary approaches including neurobiology, molecular biology, AI/machine learning, and clinical data by January 18, 2026.
BioMed X (search), a leading external innovation hub for pharmaceutical research, announced today the launch of a new collaborative research project with AbbVie (search), hosted at the BioMed X Institute in New Haven, Connecticut. The project focuses on developing "Circuit-Based Model Systems of Anhedonia (search)," targeting one of the most challenging and poorly treated symptoms of depression (search) and several other psychiatric conditions (search).
Research Focus and Objectives
Anhedonia (search), defined as the diminished ability to experience pleasure, involves a complex interplay of multiple neurotransmitter systems (search) and interconnected brain regions including the mesocorticolimbic pathway (search). The collaboration will concentrate on identifying specific mechanisms that underpin this debilitating symptom, using patient-derived data to validate mechanistic insights wherever possible.
The research aims to uncover the entangled microcircuits and molecular targets disrupted in anhedonia (search), with potential profound implications for treating depression (search) and related disorders. The project prioritizes proposals that integrate interdisciplinary approaches, including neurobiology, molecular biology, AI/machine learning, and clinical data.
Global Research Call
BioMed X (search) and AbbVie (search) have issued a global call for applications, inviting researchers worldwide to submit bold proposals for innovative research projects. Interested researchers can submit their project proposals via the BioMed X Career Space by January 18, 2026.
Mark Johnston, CEO of BioMed X (search) USA, commented: "Partnering with AbbVie (search) on this new anhedonia (search) project allows us to combine expertise in neuroscience, molecular biology, and clinical translation. Together, we aim to tackle the fundamental mechanisms of anhedonia, which could have profound implications for the treatment of depression (search) and other related disorders."
Expanding Partnership
This neuroscience collaboration represents the third research project between BioMed X (search) and AbbVie (search). Their partnership began in 2015 with a research group focused on Alzheimer's disease (search) at the BioMed X Institute in Heidelberg, Germany. More recently, in 2023, the partners launched their first U.S.-based project in New Haven focused on immunology and tissue engineering.
Research Infrastructure
BioMed X (search) operates as an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. The institute functions at the interface between academia and industry, performing biomedical research and drug discovery across multiple therapeutic areas including oncology, immunology, neuroscience, women's health, cardiometabolic diseases, platform technologies, and artificial intelligence.
All research projects are supported by leading pharmaceutical companies or other external funding sources and conducted by early-career scientists recruited from top institutions globally. This model combines global crowdsourcing with local incubation of research talents and ideas to address major challenges in biomedical research.